Monitor for additional insider sales or commentary around upcoming earnings or clinical trial updates; current activity is within normal range for a mid-cap biotech executive but warrants attention if trend continues.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 6 $99.41entry
- T+1 · 8mo ago +2.93%α +2.08% · $102.32
- T+5 · 8mo ago −1.49%α +0.04% · $97.93
- T+20 · 8mo ago +4.33%α +6.37% · $103.71
- T+60 · 6mo ago −6.44%α −19.22% · $93.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 24,993 shares in open-market transactions over two days, realizing approximately $2.44 million in proceeds. The sales were accompanied by the exercise of derivative securities for 16,912 shares, with minimal cash outlay. The total open-market sell value represents a small fraction of Nuvalent's $7.7B market cap.
Key Financial Metrics
Key Facts
- Chief Scientific Officer Henry E. Pelish sold 24,993 shares in open-market transactions on March 12 and 13, 2026, for total proceeds of $2,444,145.87.
- Pelish also exercised derivative securities for 16,912 shares, with a nominal cost of $160,072.08 and one tranche at $0 (non-cash).
- Total open-market sale value: ~$2.44M, representing 0.03% of Nuvalent’s $7.7B market cap.
- All transactions were reported on Form 4 and appear to be part of a pre-arranged trading plan or portfolio diversification.
Financial Impact
$2.44 million in open-market share sales by a C-suite executive
Risk Factors
- Perception of insider confidence erosion if further sales occur.
- Potential for short-term stock price sensitivity if market misinterprets the sales as negative signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-NUVL-1773693145016 |
Track record
18 reports on NUVL
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 4 of 8 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers